Abstract:S4.1 Treatment of rare mold infections in 2021: the role of new and old antifungals, September 22, 2022, 10:30 AM - 12:00 PMBackground & Objectives: The NRCMA oversees the surveillance of invasive fungal diseases in France. As part of our expertise, we perform antifungal susceptibility testing based on European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology on all isolates. The antifungal profiles help us monitor the emergence of resistant isolates, determine the susceptibility pattern of wild-type strains to new antifungals, and in specific cases, determine the relationship between clinical failure and selection/emergence of a less susceptible isolate.We review the Minimum inhibitory concentrations (MIC) distribution of eight antifungals on clinical isolates of filamentous fungi identified at the NRCMA from 2003 to 2021.MethodsSpecies identification was performed by a combination of morphological features and multilocus sequencing. Only strains that produced enough conidia or spores were tested. In vitro susceptibility testing was performed according to the EUCAST procedure. Eight antifungal agents were used: triazoles [itraconazole, voriconazole, posaconazole, isavuconazole (since 2015)], echinocandins (caspofungin, micafungin), amphothericin B, and terbinafine. The concentrations inhibiting 50% (MIC50) and 90% (MIC90) of the isolates were determined for species with at least 5 and 10 isolates, respectively. For Aspergillus fumigatus isolates exhibiting high azole MICs, we sequenced the cyp51A gene for mutation screening.ResultsMICs were obtained for 3343 pathogenic strains. We identified Aspergillus spp. including cryptic species (32%), Fusarium spp. (21%), Mucorales (18%), phaeohyphomycetes (10%), i.e., Alternaria spp., Curvularia spp., Fonsecaea, Exophiala, Phaeoacremonium , rare hyphomycetes (9%), i.e., Rasamsonia, Paecilomyces, Trichoderma, Scopulariopsis. Scedosporium spp. (7%) and emergent pathogens such as Nannizziopsis obscura (1%), dimorphic fungi (1%), or to a less extent basidiomycetous molds. Examples of MIC results are presented in Table 1.For the nine genera of the order Mucorales, amphotericin B (AmB) exhibited low MICs except for Cunninghamella species and Saksenaea vasiformis . Posaconazole had variable activity depending on the species (high MIC values were observed for Mucor species) while voriconazole and echinocandins had none.In section Fumigati, amphotericin B MIC values were high due to the intrinsic resistance of cryptic species Aspergillus lentulus and A. udagawae. Other cryptic species were identified such as A. hiratsukae isolates which exhibited low MICs to all antifungals.Members of Aspergillus section Nidulantes such as A. nidulans and A. quadrilineatus showed variable MICs to caspofungin and amphotericin B.Among melanized fungi, Alternaria infectoria and A. alternata species group displayed low MICs of all azoles with the exception of voriconazole.Four Exophiala species were analyzed and had similar azole MICs, E. spinifera being the species with the lowest values.Multi-drug resistant profiles were observed especially in species belonging to Microascales such as Lomentospora prolificans, Microascus cirrosus , and Scopulariopsis brevicaulis . Members of Fusarium species complexes had predictably high MIC values to all antifungals including isavuconazole. Only Fusarium dimerum species complex had low MICs to amphotericin B.Further distribution analysis is ongoing. These large datasets provide a baseline for monitoring the emergence of antifungal resistance in our country and supports the fact that MIC determination should be performed for rare/emergent species and also in case of infections due to cryptic species, which would benefit patient management.

In vitro activities of nine antifungal agents against rare pathogenic fungi.

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Comparative Evaluation of ATB FUNGUS 3 Procedure and CLSI M27-A2 Broth Microdilution Method for Antifungal Susceptibility Testing of Pathogenic Yeasts

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

In Vitro Activities of Nine Antifungal Drugs and Their Combinations against Phialophora verrucosa

S4.1d In vitro activity of eight antifungals against 3343 filamentous pathogenic fungi collected during 18 years at the French National Reference Center for invasive mycosis and antifungals

In vitro activities of six antifungal agents and their combinations against Chaetomium spp.

In Vitro Activities of Nine Antifungal Drugs Against 81 Phialophora and Cyphellophora Isolates.

Antifungal susceptibility test for pathogenic Fusarium spp in vitro

In Vitro Susceptibility Testing of Aspergillus Spp. Against Voriconazole, Itraconazole, Posaconazole, Amphotericin B and Caspofungin

In Vitro Activities of Five Antifungal Agents Against Pathogenic Exophiala Species

Antifungal Susceptibility Testing of 100 Clinical Isolates of Pathogenic Yeasts

In Vitro Activities of a Wide Panel of Antifungal Drugs against Various Scopulariopsis and Microascus Species

Analysis of antifungal susceptibility in vitro and fungi distribution in clinics

Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis

In vitro susceptibility testing of eight antifungal agents against pathogenic fungi isolated from superficial mycoses

<i>In Vitro</i> Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi

Evaluation of in vitro antifungal activities of six antifungal agents against dermatophytes

In vitro interactions between antifungals and tacrolimus against Fusarium solani

In Vitro Interactions Between Antifungals and Cyclosporin A Against Fusarium Solani

In vitro antifungal susceptibility of 80 Cryptococcus neoformans isolates